TGFB1 and prostate neoplasm: Advanced primary prostate tumors often metastasize to the bone, potentially reflecting parallel events whereby bone-derived TGF-β offers an advantage to SMAD4-overexpressing prostate tumor cells and providing a possible therapeutic target in the TGF-β pathway.